Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Medicare ACOs in Premier Inc. Collaborative Outperform Peers in Shared Savings by 21 Percent
Medicare ACOs in Premier Inc. Collaborative Outperform Peers in Shared Savings by 21 Percent


Medicare Accountable Care Organizations (ACOs) participating in the Premier Inc. (NASDAQ: PINC) Population Health Management Collaborative (PHMC) have outperformed their peers by 21 percent in

Lantheus Holdings to Host Fourth Quarter and Full Year 2019 Earnings Conference Call on February 25, 2020 at 8:00 a.m. Eastern Time
Lantheus Holdings to Host Fourth Quarter and Full Year 2019 Earnings Conference Call on February 25, 2020 at 8:00 a.m. Eastern Time


Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Tuesday, February 25, 2020, to discuss its financial and operating

Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020
Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will

European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)


Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved VYNDAQEL® (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary

European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)


Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved VYNDAQEL® (tafamidis), a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary

NanoString to Present at the 40th Annual Cowen Healthcare Conference
NanoString to Present at the 40th Annual Cowen Healthcare Conference


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that the company’s management is scheduled to present at the 40th

Canopy Growth: Das war der Befreiungsschlag!
Canopy Growth: Das war der Befreiungsschlag!

Wie ein zu Barrons gehörendes bedeutendes Online-Finanzportal berichtet, würden die Anleger billiges Marihuana bevorzugen. Canopy Growth (WKN: A140QA) sei dabei derjenige Branchenplayer, der im

Lysogene Reports its Cash Position as of 31 December 2019
Lysogene Reports its Cash Position as of 31 December 2019


Regulatory News:



Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today

Canopy Growth: Was Aurora kann...
Canopy Growth: Was Aurora kann...

...kann Canopy Growth (WKN: A140QA) schon lange. Nein, Canopy kann es sogar viel besser. Der Cannabis-Marktführer meldet heute Quartalszahlen, die im Gegensatz zu den Horrorzahlen von Aurora

Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results
Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.



Fourth Quarter 2019 Highlights:




  • Revenue grew 37% versus the

Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results
Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.



Fourth Quarter 2019 Highlights:




  • Revenue grew 37% versus the

Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24
Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24


Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’

Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the

Illumina to Webcast Upcoming Investor Conference Presentations
Illumina to Webcast Upcoming Investor Conference Presentations


Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.



SVB Leerink Global

Illumina to Webcast Upcoming Investor Conference Presentations
Illumina to Webcast Upcoming Investor Conference Presentations


Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.



SVB Leerink Global

Illumina to Webcast Upcoming Investor Conference Presentations
Illumina to Webcast Upcoming Investor Conference Presentations


Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.



SVB Leerink Global

Sangamo Therapeutics Appoints John Markels to Its Board of Directors
Sangamo Therapeutics Appoints John Markels to Its Board of Directors


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general

Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference
Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference


Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 9th Annual SVB Leerink Global Healthcare Conference on

Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases
Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases


Regulatory News:



Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today

NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer
NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer


Regulatory News:



NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today

NanoString to Release Fourth Quarter and Fiscal Year 2019 Financial Results and Host Conference Call on Wednesday, February 26, 2020
NanoString to Release Fourth Quarter and Fiscal Year 2019 Financial Results and Host Conference Call on Wednesday, February 26, 2020


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that the Company will release fourth quarter and fiscal year 2019

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 5, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Agilent Technologies Announces Twist Bioscience Agrees to Pay $22.5 Million Settlement in IP Litigation
Agilent Technologies Announces Twist Bioscience Agrees to Pay $22.5 Million Settlement in IP Litigation


Agilent Technologies Inc. (NYSE: A) today announced it has reached an agreement with Twist Bioscience under which Twist has agreed to pay Agilent a sum of $22.5 million to settle Agilent’s claims

Xencor to Present at Upcoming Investor Conferences
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company

Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors


Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. has joined the company’s Board of Directors, effective February 4, 2020. Dr. Gottlieb is currently a special partner at the